Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2016 - 2025)

Spyre Therapeutics' Other Non-Current Liabilities history spans 11 years, with the latest figure at $26.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 27.14% year-over-year to $26.7 million; the TTM value through Dec 2025 reached $26.7 million, down 27.14%, while the annual FY2025 figure was $26.7 million, 27.14% down from the prior year.
  • Other Non-Current Liabilities reached $26.7 million in Q4 2025 per SYRE's latest filing, up from $3.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $164.4 million in Q2 2023 to a low of $8000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $28.3 million, with a median of $20.7 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: surged 795.65% in 2021, then plummeted 96.12% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $16000.0 in 2021, then crashed by 50.0% to $8000.0 in 2022, then surged by 516275.0% to $41.3 million in 2023, then dropped by 11.35% to $36.6 million in 2024, then decreased by 27.14% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Other Non-Current Liabilities are $26.7 million (Q4 2025), $3.2 million (Q3 2025), and $16.5 million (Q1 2025).